drugset / Trial / NCT01757756

Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects

NCT01757756

Phase 1 Completed 12 enrolled Pfizer
NaSingle-groupSingle-blindBasic science

Summary

This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of Pf-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.

Timeline

Start
2012-10
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 3 mg
Subject PF-05175157 Small molecule 200 mg Oral